Do you want to access to this and other private contents?
Log in if you are a subscriber or click here to request service

Palforzia of Aimmune is the first treatment for peanut allergy in the EU

Approved the use of the biological drug, developed by Nestlé health science company

The European Commission has approved the use of Palforzia (defatted powder of Arachis hypogaea L.) for the treatment of peanut allergy in the European Union (EU). Developed by Aimmune Therapeutics, Inc., a Nestlé Health Science Company, Palforzia is an oral immunotherapy indicated in patients aged 4 to 17 years, who have a confirmed diagnosis of peanut allergy. Palforzia may be continued in patients...

hef - 16007
Bruxelles, Belgio, 01/08/2021 10:53
EFA News - European Food Agency

Similar

HealthNestlé /2. Materna: new nutritional solutions for pregnancy and fertility

Products aimed at alleviating recurring related symptoms, such as nausea and vomiting

Nestlé has introduced two new nutritional solutions, Materna Pre and Materna Nausea, designed to support female fertility and relieve some of the pregnancy-related symptoms that women may experience,... more

HealthSupplements. Italy records: 30 million have used them in the last year

At a national level, the sector boasts sales of almost 300 thousand tons and a turnover of 4.5 billion euros

A healthy sector that looks to the future, focusing on innovation and research. And that hopes for a harmonized regulation at European level for food supplements to make Italian companies increasingly... more

HealthNestlé supports balanced diets

Symposium in Lausanne reiterates need to rethink impact of nutrition on health

The debate about nutrition and health is constantly evolving. This includes not only the need to focus on the impact of individual nutrients, but also to consider the broader context of balanced meals... more

◄ Previous page